Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
The Journal of Pharmacology and Experimental Therapeutics
|
March 12, 2015
Trapping Poly(ADP-Ribose) Polymerase
Yuqiao Shen, Mika Aoyagi-Scharber, Bing Wang
Plos One
|
July 7, 2018
Utilizing ExAC to assess the hidden contribution of variants of unknown significance to Sanfilippo Type B incidence
Wyatt T Clark, G Karen Yu, Mika Aoyagi-Scharber, et al.
Journal of Medicinal Chemistry
|
December 15, 2015
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
Bing Wang, Daniel Chu, Ying Feng, et al.
Acta Crystallographica. Section F, Structural Biology Communications
|
September 9, 2014
Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone
Mika Aoyagi-Scharber, Anna S Gardberg, Bryan K Yip, et al.
Plos One
|
January 19, 2019
BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis
Gouri Yogalingam, Amanda R Luu, Heather Prill, et al.
Molecular Therapy. Methods & Clinical Development
|
July 17, 2019
Differential Uptake of NAGLU-IGF2 and Unmodified NAGLU in Cellular Models of Sanfilippo Syndrome Type B
Heather Prill, Amanda Luu, Bryan Yip, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 5, 2015
Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism
Daniel J Wendt, Melita Dvorak-Ewell, Sherry Bullens, et al.
Plos One
|
January 3, 2025
Intracerebroventricular administration of a modified hexosaminidase ameliorates late-stage neurodegeneration in a GM2 mouse model
Manuel E Lopez, Daniel Wendt, Roger Lawrence, et al.
Molecular Therapy. Methods & Clinical Development
|
July 1, 2017
Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice
Mika Aoyagi-Scharber, Danielle Crippen-Harmon, Roger Lawrence, et al.
Drug Delivery and Translational Research
|
January 17, 2020
Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type B
Anita Grover, Danielle Crippen-Harmon, Lacey Nave, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
The Journal of Pharmacology and Experimental Therapeutics
|
March 12, 2015
Trapping Poly(ADP-Ribose) Polymerase
Yuqiao Shen, Mika Aoyagi-Scharber, Bing Wang
Plos One
|
July 7, 2018
Utilizing ExAC to assess the hidden contribution of variants of unknown significance to Sanfilippo Type B incidence
Wyatt T Clark, G Karen Yu, Mika Aoyagi-Scharber, et al.
Journal of Medicinal Chemistry
|
December 15, 2015
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
Bing Wang, Daniel Chu, Ying Feng, et al.
Acta Crystallographica. Section F, Structural Biology Communications
|
September 9, 2014
Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone
Mika Aoyagi-Scharber, Anna S Gardberg, Bryan K Yip, et al.
Plos One
|
January 19, 2019
BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis
Gouri Yogalingam, Amanda R Luu, Heather Prill, et al.
Molecular Therapy. Methods & Clinical Development
|
July 17, 2019
Differential Uptake of NAGLU-IGF2 and Unmodified NAGLU in Cellular Models of Sanfilippo Syndrome Type B
Heather Prill, Amanda Luu, Bryan Yip, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 5, 2015
Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism
Daniel J Wendt, Melita Dvorak-Ewell, Sherry Bullens, et al.
Plos One
|
January 3, 2025
Intracerebroventricular administration of a modified hexosaminidase ameliorates late-stage neurodegeneration in a GM2 mouse model
Manuel E Lopez, Daniel Wendt, Roger Lawrence, et al.
Molecular Therapy. Methods & Clinical Development
|
July 1, 2017
Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice
Mika Aoyagi-Scharber, Danielle Crippen-Harmon, Roger Lawrence, et al.
Drug Delivery and Translational Research
|
January 17, 2020
Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type B
Anita Grover, Danielle Crippen-Harmon, Lacey Nave, et al.
Page
of 2